Acrivon Therapeutics reported second quarter 2026 financial results with a net loss of $18.0 million, compared to $21.0 million in the prior year period. Research and development expenses decreased to $13.8 million from $16.2 million, while general and administrative expenses fell to $4.8 million from $6.5 million. The company held cash, cash equivalents, and marketable securities of $90.0 million as of June 30, 2026, which is expected to fund operations into the fourth quarter of 2027. Clinically, ACR-368 dosing continues in its Phase 2b study for serous endometrial cancer, with a prespecified interim analysis anticipated in the second half of 2026. Additionally, ACR-2316 has advanced into the randomized dose expansion phase of its Phase 1/2 trial, showing durable single-agent activity and a favorable safety profile across multiple tumor types.

At its 2026 annual meeting held on June 17, 2026, Acrivon Therapeutics, Inc. stockholders approved the Amended and Restated 2022 Equity Incentive Plan. This plan increases the aggregate share reserve to 8,606,723 shares, including a 3,000,000 share increase. The plan also includes an automatic annual share reserve increase of 5% of fully diluted shares through 2032. Additionally, Michael Tomsicek and Charles Baum were elected as Class I directors, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm. Acrivon Therapeutics, Inc. is a biotechnology company focused on developing therapeutics.